Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : FDA asks Pfizer and Moderna to expand COVID-19 vaccine pediatric studies- NYT

07/26/2021 | 01:05pm EDT

July 26 (Reuters) - U.S. regulators have asked Pfizer Inc -BioNTech and Moderna Inc to expand the size of ongoing trials testing their COVID-19 vaccines in children aged between five and 11, the New York Times reported on Monday.

The Food and Drug Administration has indicated that the current strength of the studies was inadequate to detect the rare side effects, including myocarditis, an inflammation of the heart muscle, and pericarditis, an inflammation of the lining around the heart, the report said. (https://nyti.ms/3xgzuWZ)

The health regulator has asked the companies to include 3,000 children in their trials, almost double the original number of study participants, the report said, citing people familiar with the matter.

FDA, Pfizer and Moderna did not immediately respond to Reuters request for comment. (Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)


© Reuters 2021
All news about MODERNA, INC.
08:12aMODERNA : U.S. COVID-19 booster debate moves to FDA vaccine advisory committee
RE
08:08aLATEST : Cambodia vaccinating kids ages 6 to 11 for school
AQ
07:00aMODERNA : U.S. COVID-19 booster debate moves to FDA vaccine advisory committee
RE
05:06aMODERNA : Ekiti Denies Administering Spoilt Covid-19 Vaccines On Citizens
AQ
05:06aMODERNA : No Issues With Covid-19 Vaccines Storage in Ekiti - Commissioner
AQ
09/16Pfizer-BioNTech, Moderna's Booster COVID-19 Shots Enters Real-Time Review in ..
MT
09/16UK Study to Mix Three COVID-19 Vaccine Doses in Adolescents
MT
09/16Healthcare Shares Slip as Investors Mull Delta Spread -- Healthcare Roundup
DJ
09/16MODERNA : U.S. administers 383 mln doses of COVID-19 vaccines - CDC
RE
09/16GOODBYE PFIZER, HELLO COMIRNATY : top COVID-19 vaccines renamed in Canada
AQ
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 20 348 M - -
Net income 2021 12 529 M - -
Net cash 2021 12 947 M - -
P/E ratio 2021 14,8x
Yield 2021 -
Capitalization 178 B 178 B -
EV / Sales 2021 8,11x
EV / Sales 2022 7,50x
Nbr of Employees 1 300
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Last Close Price 440,65 $
Average target price 306,23 $
Spread / Average Target -30,5%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.321.80%177 867
LONZA GROUP AG36.36%62 278
IQVIA HOLDINGS INC.43.91%49 407
CELLTRION, INC.-25.63%31 021
SEAGEN INC.-12.32%27 940
PHARMARON BEIJING CO., LTD.74.42%24 534